Tesamorelin 2 - Ultima Pharmaceuticals

Tesamorelin is a synthetic peptide from the growth hormone-releasing hormone (GHRH) family that specifically stimulates growth hormone secretion. Approved by the FDA under the brand name Egrifta, tesamorelin is used primarily to reduce abdominal fat in HIV-positive individuals with lipodystrophy. It works by acting on the pituitary to enhance natural growth hormone release, which in turn increases levels of IGF-1, a key factor in metabolism, muscle growth, and fat reduction. Clinical studies have demonstrated that 2 mg of tesamorelin daily significantly raises growth hormone and IGF-1 levels, resulting in reduced trunk fat, increased lean body mass, and improved lipid profiles. While generally well-tolerated, side effects may include injection site reactions and mild joint pain​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tesamorelin 2 by Ultima Pharmaceuticals, consult with your doctor or healthcare professional.